NASDAQ$NUVL
Nuvalent Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Nuvalent reported its fourth quarter and full year 2021 financial results and pipeline progress.
Nuvalent reported a net loss of $17.3 million for the fourth quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $288.1 million as of December 31, 2021. The IND application for NVL-655 was cleared by the FDA, and enrollment is ongoing in the ARROS-1 trial of NVL-520.
- NVL-655 IND was cleared by the FDA, supporting the planned initiation of the ALKOVE-1 Phase 1/2 clinical trial in Q2 2022.
- Enrollment is ongoing in the ARROS-1 trial of NVL-520 for advanced ROS1-positive NSCLC and other solid tumors.
- The discovery pipeline continues to advance toward two development candidate nominations in 2022.
- Cash, cash equivalents and marketable securities were $288.1 million as of December 31, 2021.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
-$2.43M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2021
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro